These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35254887)

  • 1. A pharmacoeconomic study comparing the use of mycophenolate mofetil or cyclophosphamide as induction therapy in lupus nephritis patients in Egypt.
    Khattab NM; Abbassi M; A Raafat H; Farid S
    Lupus; 2022 Apr; 31(4):505-516. PubMed ID: 35254887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of cyclophosphamide and non-cyclophosphamide in the induction therapy of Malaysian lupus nephritis patients.
    Rosli FZ; Shaharir SS; Abdul Gafor AH; Mohd R; Aizuddin AN; Osman S
    Lupus; 2022 Aug; 31(9):1138-1146. PubMed ID: 35608373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial.
    Sedhain A; Hada R; Agrawal RK; Bhattarai GR; Baral A
    BMC Nephrol; 2018 Jul; 19(1):175. PubMed ID: 29996800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
    Feng X; Gu F; Chen W; Liu Y; Wei H; Liu L; Yin S; Da Z; Sun L
    Chin Med J (Engl); 2014; 127(21):3718-23. PubMed ID: 25382325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction therapy for pediatric onset class IV lupus nephritis: Mycophenolate Mofetil versus Cyclophosphamide.
    Chbihi M; Eveillard LA; Riller Q; Brousse R; Berthaud R; Quartier P; Salomon R; Charbit M; Avramescu M; Biebuyck N; Dehoux L; Garcelon N; Duong-Van-Huyen JP; Bader-Meunier B; Boyer O
    J Nephrol; 2023 Apr; 36(3):829-839. PubMed ID: 36208405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.
    Zhu B; Chen N; Lin Y; Ren H; Zhang W; Wang W; Pan X; Yu H
    Nephrol Dial Transplant; 2007 Jul; 22(7):1933-42. PubMed ID: 17405792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pro: The use of calcineurin inhibitors in the treatment of lupus nephritis.
    Mok CC
    Nephrol Dial Transplant; 2016 Oct; 31(10):1561-6. PubMed ID: 27591327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparison Of Mycophenolate Mofetil And Cyclophosphamide As Lupus Nephritis Induction Therapy.
    Gul H; Mushtaq MS; Salim B; Samreen S; Nasim A; Khan M
    J Ayub Med Coll Abbottabad; 2020; 32(4):454-458. PubMed ID: 33225643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate mofetil vs. cyclophosphamide-based induction regimens for lupus nephritis: Outcomes at a tertiary care centre in Lahore, Pakistan.
    Saeed MA; Khan A; Naeem F; Ahmad NM
    J Pak Med Assoc; 2024 May; 74(5):868-873. PubMed ID: 38783432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: A systematic review and meta-analysis.
    Jiang YP; Zhao XX; Chen RR; Xu ZH; Wen CP; Yu J
    Medicine (Baltimore); 2020 Sep; 99(38):e22328. PubMed ID: 32957400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.
    Prasad N; Kurian J; Agarwal V; Bhadauria D; Behera M; Yacha M; Kushwaha R; Agrawal V; Jain M; Gupta A
    Lupus; 2020 Jul; 29(8):845-853. PubMed ID: 32437258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis.
    Basu B; Roy B; Babu BG
    Pediatr Nephrol; 2017 Jun; 32(6):1013-1021. PubMed ID: 28191596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
    Rathi M; Goyal A; Jaryal A; Sharma A; Gupta PK; Ramachandran R; Kumar V; Kohli HS; Sakhuja V; Jha V; Gupta KL
    Kidney Int; 2016 Jan; 89(1):235-42. PubMed ID: 26489028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study comparing the childhood arthritis and rheumatology research alliance consensus treatment plans for induction therapy of juvenile proliferative lupus nephritis.
    Cooper JC; Rouster-Stevens K; Wright TB; Hsu JJ; Klein-Gitelman MS; Ardoin SP; Schanberg LE; Brunner HI; Eberhard BA; Wagner-Weiner L; Mehta J; Haines K; McCurdy DK; Phillips TA; Huang Z; von Scheven E;
    Pediatr Rheumatol Online J; 2018 Oct; 16(1):65. PubMed ID: 30348175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
    Joo YB; Kang YM; Kim HA; Suh CH; Kim TJ; Park YW; Lee J; Lee JH; Yoo DH; Bae SC; Lee HS; Bang SY
    Int J Rheum Dis; 2018 May; 21(5):1031-1039. PubMed ID: 29611341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
    Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR
    Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term renal survival of paediatric patients with lupus nephritis.
    Demir S; Gülhan B; Özen S; Çeleğen K; Batu ED; Taş N; Orhan D; Bilginer Y; Düzova A; Ozaltin F; Topaloğlu R
    Nephrol Dial Transplant; 2022 May; 37(6):1069-1077. PubMed ID: 33826705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment for lupus nephritis.
    Henderson L; Masson P; Craig JC; Flanc RS; Roberts MA; Strippoli GF; Webster AC
    Cochrane Database Syst Rev; 2012 Dec; 12():CD002922. PubMed ID: 23235592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High- and low-dose cyclophosphamide in Egyptian lupus nephritis patients: a multicenter retrospective analysis.
    Elaziz MMA; Gamal SM; Fayed A; Abu-Zaid MH; Ghoniem SA; Teleb DA
    Z Rheumatol; 2024 Feb; 83(Suppl 1):115-123. PubMed ID: 37582953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis.
    Koo HS; Kim YC; Lee SW; Kim DK; Oh KH; Joo KW; Kim YS; Ahn C; Han JS; Kim S; Chin HJ
    Lupus; 2011 Nov; 20(13):1442-9. PubMed ID: 21951944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.